Literature DB >> 17671381

Symptom resolution does not predict healing of erosive oesophagitis in Chinese.

Ting Kin Cheung1, Wai Man Wong, Nina Y H Wong, Chi Kuen Chan, James Fung, Man Fung Yuen, Annie O O Chan, Teresa S M Tong, Benjamin C Y Wong.   

Abstract

BACKGROUND: Previous studies suggested that Chinese have a milder spectrum of gastro-oesophageal reflux disease and a lower dose of proton pump inhibitors (PPI) is sufficient for the control of symptoms as compared with the Western population. AIMS: To determine if 8 weeks of esomeprazole 20 mg daily would be adequate for both symptom resolution and oesophagitis healing in Chinese patients and the predictive factors for the response.
METHODS: 66 patients with oesophagitis were included. Oesophagitis severity was graded by Los Angeles (LA) classification. 61 patients underwent 24-hour ambulatory pH study at baseline. All were given esomeprazole 20 mg daily for 8 weeks. Symptom response and healing of oesophagitis was assessed at the end of the treatment period.
RESULTS: 75.8% of the patients had complete reflux symptom resolution but only 48% had complete healing of the oesophagitis at endoscopy after 8 weeks of treatment. LA classification grading at baseline endoscopy (p < 0.0001) and total number acid reflux episodes on 24-hour pH monitoring prior to treatment (p = 0.007) were both good predictors of oesophagitis healing but not for symptom resolution.
CONCLUSIONS: Our results suggested that 8 weeks of lower dose PPI is not sufficient for oesophagitis healing. Symptom resolution with PPI does not predict oesophagitis healing in Chinese. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671381     DOI: 10.1159/000106453

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

1.  Combination of angiotensin II receptor blockers promotes proton pump inhibitor-based healing of reflux esophagitis.

Authors:  Hiroto Miwa; Michio Hongo; Motoyasu Kusano
Journal:  J Gastroenterol       Date:  2011-11-01       Impact factor: 7.527

2.  Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial.

Authors:  Victoria P Y Tan; Wai M Wong; Ting K Cheung; Kam C Lai; Ivan F N Hung; Pierre Chan; Roberta Pang; Benjamin C Y Wong
Journal:  J Gastroenterol       Date:  2011-05-03       Impact factor: 7.527

3.  Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.

Authors:  Kathleen W Wyrwich; Reema Mody; Lois M Larsen; Misun Lee; Neesha Harnam; Dennis A Revicki
Journal:  Qual Life Res       Date:  2010-02-27       Impact factor: 4.147

Review 4.  Strategy for treatment of nonerosive reflux disease in Asia.

Authors:  Toru Hiyama; Masaharu Yoshihara; Shinji Tanaka; Ken Haruma; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

5.  The Frequencies of Gastroesophageal and Extragastroesophageal Symptoms in Patients with Mild Erosive Esophagitis, Severe Erosive Esophagitis, and Barrett's Esophagus in Taiwan.

Authors:  Sung-Shuo Kao; Wen-Chih Chen; Ping-I Hsu; Seng-Kee Chuah; Ching-Liang Lu; Kwok-Hung Lai; Feng-Woei Tsai; Chun-Chao Chang; Wei-Chen Tai
Journal:  Gastroenterol Res Pract       Date:  2013-08-12       Impact factor: 2.260

6.  Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole.

Authors:  Justin C Y Wu; Bor-Shyang Sheu; Ming-Shiang Wu; Yong Chan Lee; Myung-Gyu Choi
Journal:  J Neurogastroenterol Motil       Date:  2020-01-30       Impact factor: 4.924

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.